 Pepducins for over 15 different GPCRs have been successfully produced, several of which have shown activity in preclinical "in vivo" models.An anti-PAR4 pepducin extended bleeding time in mice and protected against systemic platelet activation and thrombosis.A CXCR4 agonist pepducin mobilizes bone marrow hematopoietic cells.